The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor
Abstract
Summary: Interleukin‐5 is a Th2 homodimeric cytokine involved in the differentiation, maturation, migration, development, survival, trafficking and effector function of blood and local tissue eosinophils, in addition to basophils and mast cells. The IL‐5 receptor (IL‐5R) consists of an IL‐5‐specific α subunit that interacts in conformationally dynamic ways with the receptor's βc subunit, an aggregate of domains it shares with binding sites of IL‐3 and granulocyte‐macrophage colony‐stimulating factor. IL‐5 and IL‐5R drive allergic and inflammatory immune responses characterizing numerous diseases, such as asthma, atopic dermatitis, chronic obstructive pulmonary disease, eosinophilic gastrointestinal diseases, hyper‐eosinophilic syndrome, C hurg‐S trauss syndrome and eosinophilic nasal polyposis. Although corticosteroid therapy is the primary treatment for these diseases, a substantial number of patients exhibit incomplete responses and suffer side‐effects. Two monoclonal antibodies have been designed to neutralize IL‐5 (mepolizumab and reslizumab). Both antibodies have demonstrated the ability to reduce blood and tissue eosinophil counts. One additional monoclonal antibody, benralizumab (MEDI‐563), has been developed to target IL‐5R and attenuate eosinophilia through antibody‐dependent cellular cytotoxicity. All three monoclonal antobodies are being clinically evaluated. Antisense oligonucleotide technology targeting the common βc IL‐5R subunit is also being used therapeutically to inhibit IL‐5‐mediated effects (TPI ASM8). Small interfering RNA technology has also been used therapeutically to inhibit the expression of IL‐5 in animal models. This review summarizes the structural interactions between IL‐5 and IL‐5R and the functional consequences of such interactions, and describes the pre‐clinical and clinical evidence supporting IL‐5R as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Cited by
Eosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Self-citationTargeting eosinophils in allergy, inflammation and beyond
Fulkerson, P. C., & Rothenberg, M. E. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3838 · Cited by 482
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
Interleukin-5 in the Pathophysiology of Severe Asthma.
Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., & Heffler, E. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01514 · Cited by 337
Metadata
- Authors
- Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., & Geba, G. P.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2011-09-23
- Volume
- 42
- Issue
- 5
- Pages
- 712-737
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2056743382
- Cited by
- 215
- References
- 3
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor. https://app.cochat.ai/papers/10.1111/j.1365-2222.2011.03854.x
- The paper
- Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., & Geba, G. P. (2012). Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2011.03854.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.